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Multiple facets of macrophages in renal injury. Macrophage in-
filtration is a common feature of renal disease and their presence
has been synonymous with tissue damage and progressive renal
failure. More recently work has focused on the heterogeneity of
macrophage activation and in particular their ability to curtail
inflammation and restore normal function. This has led to the
view that it is macrophage function rather than their number
that is important in determining the outcome of inflammatory
disease. This review will focus on the pathways that regulate
macrophage infiltration and activation and how these could be
manipulated to control renal inflammatory disease. In particu-
lar, the ability of specific cell surface receptors and intracellular
signaling pathways to control macrophage activation and how
macrophages can be genetically manipulated to develop prop-
erties that favor resolution over ongoing injury.
Macrophage infiltration is one of the most striking fea-
tures of glomerular and tubulointerstitial disease, and the
degree of mononuclear cell infiltrate has been used to pre-
dict subsequent progression [1]. Nephrologists have gen-
erally viewed macrophages as cells that, on entry to the
kidney, were activated to produce a range of cytokines,
chemokines, and other mediators that were responsible
for the tissue injury and subsequent scarring. This was
part of a more general paradigm that emphasized the im-
portance of the destructive properties of inflammation in
host defense against infection and for tumor destruction,
and consequently the particular macrophage properties
able to prosecute it.
This restricted view has changed radically over the
last 5 years. Inflammation is now viewed more globally
as a highly regulated response to injury designed to re-
store normal function with the minimal tissue damage
possible. This highlights a much more complex role for
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macrophages in maintaining tissue integrity that includes
patrolling tissues to sense the presence of infection and
other types of injury; responding appropriately and often
destructively to the damage identified; promoting reso-
lution of acute inflammation; and then facilitating tissue
repair and restoration of normal function. This raises
the possibility of harnessing the macrophage’s natural
reparative properties therapeutically to curtail immune-
mediated injury.
The challenge is how to apply this approach to patients
with progressive renal injury. The purpose of this review
is to summarize knowledge about macrophage function
and the activation states responsible for it. The empha-
sis will be on in vivo studies, especially those of renal
inflammation and the insights they provide into what de-
termines the outcome of inflammation. We will discuss
factors that control macrophage entry into inflamed re-
nal tissue and show that macrophage function rather than
number usually dictates the severity of injury. In addi-
tion we will discuss how therapeutic interventions alter
macrophage phenotype and how macrophages can be ge-
netically modified to ameliorate renal inflammation.
MACROPHAGES IN RENAL DISEASE
In many renal diseases large numbers of infiltrating
macrophages can be identified, in particular in an-
tineutrophil cytoplasmic antibodies (ANCA)-positive
glomerulonephritis, lupus nephritis, cryoglobulinemia,
mesangioproliferative glomerulonephritis, and IgA
nephropathy [2], and interstitial macrophages are a
common feature of most forms of progressive renal
damage including those not generally considered to be
inflammatory such as diabetic nephropathy. Similarly
macrophage infiltration is a feature of a wide range of
experimental models of glomerulonephritis, including
nephrotoxic nephritis, Thy 1 nephritis, murine models
of lupus nephritis, Heymann’s nephritis, and immune
complex glomerulonephritis [3–6], as well as in a number
of nonimmune models of progressive renal damage such
as renal ablation, puromycin, and adriamycin nephrosis
and unilateral ureteric obstruction [7].
Initial studies focused on the pathogenic properties
of macrophages by using different approaches to reduce
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macrophage numbers. In a model of nephrotoxic nephri-
tis in rabbits treatment with an antimacrophage anti-
body reduced the severity of inflammation, while in-
duction of leukopenia by nitrogen mustard protected
from development of disease which could be recon-
stituted by injection of peritoneal macrophages [8, 9].
An updated version of these experiments confirmed
the pathogenic potential of macrophages in nephro-
toxic nephritis. Leukopenia was induced by cyclophos-
phamide and disease could be reconstituted by injection
either bone marrow–derived macrophages (BMDM) or
a macrophage cell line NR8383. The severity of injury
seen correlated with the numbers of macrophages in-
jected [10]. Similarly stimulation of macrophages with
interferon-c (IFN-c) before injection increased the sever-
ity of proteinuria, showing that the state of macrophage
activation is critical in determining outcome [11]. In anti-
Thy 1.1 glomerulonephritis, depletion of macrophages
using clodronate liposomes led to a reduction in mesan-
gial matrix expansion without altering proteinuria and
haematuria [12]. In puromycin nephrosis and rat renal
ablation model whole body radiation prevented progres-
sive glomerular injury with a reduction in glomerular and
interstitial macrophage infiltration [13, 14].
MACROPHAGE FUNCTION
IN INFLAMED GLOMERULI
The critical question is what functions do macrophages
perform in inflamed glomeruli and what determines this?
Macrophages are capable of producing a wide range of
potentially cytotoxic products, including proteolytic en-
zymes, reactive oxygen and nitrogen species, eicosanoids,
proinflammatory cytokines, and chemokines. Studies
over many years demonstrate production of these medi-
ators by renal macrophages. Thus macrophages isolated
from nephritic glomeruli in rats and rabbits generate reac-
tive oxygen species [15, 16]. Similarly nephritic glomeruli
from rats produce large amounts of nitric oxide [17] and
in both nephrotoxic nephritis and Heymann’s nephri-
tis macrophages are the principal source [18]. The exact
contribution of nitric oxide to glomerular injury remains
controversial with an early study showing that decreas-
ing nitric oxide production by L-arginine depletion in rat
nephrotoxic nephritis exacerbated proteinuria [19], while
a more recent study using synthetic inducible nitric ox-
ide synthase (iNOS) inhibitor in Wistar-Kyoto (WKY) rat
nephrotoxic nephritis reduced crescent formation [20]. In
vitro macrophage-derived nitric oxide and tumor necro-
sis factor-a (TNF-a) induce mesangial cell apoptosis [21],
and uptake of apoptotic mesangial cells down-regulates
macrophage inflammatory mediators [22]. These stud-
ies demonstrate that macrophages within acutely injured
glomeruli have characteristics typical of histotoxic cells.
Production of proinflammatory cytokines by
macrophages may also play a key role. TNF-a is produced
by glomerular macrophages in both MRL/lpr lupus mice
and rabbits with nephrotoxic nephritis [23–25]. Similarly
interleukin (IL)-1b production has been shown [26]
and this has led to a number of studies to inhibit these
cytokines. Blockade of either TNF-a or IL-1b was able
to suppress glomerular inflammation in a number of
disease models [27]. Treatment of rats with nephro-
toxic nephritis with IL-1 receptor antagonist (IL-1ra)
reduced macrophage infiltration, histologic markers
of injury, and the level of proteinuria [28, 29] and
IL-1ra was able to have this effect even when therapy
was commenced 7 days after onset of disease [30]. In
crescentic glomerulonephritis in WKY rats soluble TNF
receptor p55, which acts as a TNF antagonist, reduced
the severity of nephritis and crescent formation when
administered before or after the onset of disease [31].
Anti-TNF therapy using humanized mouse monoclonal
antibodies is now used in the treatment of a number of
autoimmune diseases including systemic vasculitis [32].
Both IL-1b and TNF-a signal through nuclear factor-jB
(NF-jB) and not surprisingly inhibiting NF-jB signaling
cascade with pyrrolidine dithiocarbamate (PDTC) (a
relatively nonspecific inhibitor) reduced inflammation
and glomerular expression of IL-1b , monocyte chemoat-
tractant protein-1 (MCP-1), and iNOS [33]. Macrophage
migration inhibitory factor (MIF) is another inflamma-
tory cytokine with an important role. It was originally
identified as a T cell and macrophage-derived cytokine
involved in delayed type hypersensitivity reactions
and in countering the actions of steroids [34]. It is
also produced by endothelium and tubular cells and
its expression is up-regulated in nephrotoxic nephritis
in rats [35] and in human glomerulonephritides [36].
Passive immunisation against MIF reduced macrophage
infiltration and severity of glomerular inflammation even
in established disease [37, 38].
Studies inhibiting proinflammatory mediators have
identified some of the important inflammatory media-
tors responsible for renal injury. However systemic ad-
ministration of agonists/antagonists potentially affects all
cells involved in renal inflammation rather than specifi-
cally macrophages. Despite these limitations macrophage
activation on infiltration into inflamed renal tissue has
been convincingly shown to cause injury (Fig. 1). This in
turn has directed research to determine different ways in
which macrophages can be activated and how these could
be manipulated.
MACROPHAGE ACTIVATION
Classical activation
Macrophages evolved to deal with microbial infection
and a range of receptors on the cell surface recognize
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Fig. 1. Macrophage function on entry into inflamed tissue. Monocytes
adhere to endothelium activated by the inflammatory process via inte-
grins and chemoadhesins following a chemotactic gradient [121]. Once
within the inflamed tissue they are capable of both promoting inflamma-
tion by release of chemokines, proinflammatory cytokines, proteolytic
enzymes, and reactive oxygen and nitrogen species and of promoting
resolution by release of cytokine inhibitors, regulatory cytokines [inter-
leukin (IL)-10 or transforming growth facto-b (TGF-b)] and removing
apoptotic cells with consequent anti-inflammatory effect [22]. Abbre-
viations are: MCP-1, monocyte chemoattractant protein-1; IL-1ra, IL-1
receptor antagonist; TNFR, tumor necrosis factor receptor; NO, nitric
oxide; ROS, reactive oxygen species; MIP-1a, macrophage inflamma-
tory protein-1a.
pathogen-associated molecular patterns (PAMPs), which
include Toll-like receptors (TLRs), mannose receptor
and scavenger receptor family (Table 1). TLRs recog-
nize a range of microbial products including lipopolysac-
charide (LPS) acting on TLR4, bacterial unmethylated
CpG DNA acting via TLR9 and viral double-stranded
(ds)RNA acting via TLR3 [39]. These in turn lead to acti-
vation of intracellular signaling pathways, including NF-
jB and the mitogen-activated protein kinase (MAPK).
Classical activation involves stimulation of macrophages
with two signals. The first is the engagement of TLR and
the second is provided by IFN-c from T-helper lympho-
cytes or natural killer cells. This leads to macrophage
production of nitric oxide and reactive oxygen species,
production of other proinflammatory cytokines, includ-
ing TNF-a and IL-12 and expression of major histo-
compatibility complex (MHC) class II and costimulatory
molecules which promote antigen presentation. This re-
sponse is designed to enhance microbial killing and acti-
vate adaptive immunity [40]. There is increasing evidence
that as well as binding to microbial products TLRs also
recognize endogenous ligands released by damaged tis-
sues such as heat-shock protein 60 and 70 which are lig-
ands for TLR4 [41] and dsDNA which interacts with
TLR9 [42]. Of note administration of unmethylated
CpG exacerbated disease severity in immune complex
glomerulonephritis by a TLR-dependent mechanism
[43]. Classically activated macrophages have been found
at sites of immune-mediated inflammation, including
glomerulonephritis [44], especially during the initial in-
duction of the inflammatory response. However, it is im-
portant to recognize macrophages can be activated in
other ways and display much greater functional hetero-
geneity than previously envisioned [45].
Alternative activation
The first example of this was the characterization of the
alternatively activated macrophage which develop after
exposure to IL-4 or IL-13 [46, 47]. These cells show in-
creased expression of mannose receptor and MHC class
II, increased endocytosis, decreased nitric oxide produc-
tion due to both decreased expression of iNOS and in-
creased production of arginase and increased expression
of IL-1 decoy receptor and IL-1ra [48]. Thus these cells
have decreased killing of intracellular organisms but in-
creased matrix production suggesting a role in tissue re-
pair [49].
Type II–activated macrophage
More recently Mosser [50] has identified a “type II–
activated macrophage.” They found that exposure of
macrophages to activating stimuli such as LPS or CD40L
in the presence of IgG immune complexes resulted in in-
creased IL-10 expression and reduced IL-12 expression
but with preservation of other proinflammatory cytokines
such as TNF-a and IL-6 [51, 52]. These cells in vivo fa-
vor the development of Th2 type immune responses with
increased T-cell IL-4 production and IgG class switching
by B cells [53].
Macrophage uptake of apoptotic cells
Removal of dying cells by macrophages is an essen-
tial component of normal development and in the res-
olution of inflammation allowing uptake of dying cells
before they release their potentially toxic contents [54].
Uptake of apoptotic cells results in development of
macrophage with immune inhibitory properties. Phago-
cyte ingestion of apoptotic cells is a complex process
involving a range of cell surface receptors both on the
apoptotic cells and macrophages as well as various bridg-
ing molecules between them [54]. Macrophages which
have ingested apoptotic cells develop anti-inflammatory
properties with increased expression of transforming
growth factor-b (TGF-b) and prostaglandin E2 (PGE2)
and decreased production of IL-8, TNF-a, and IL-1b [55]
and on further stimulation with LPS macrophages acti-
vated in this way increase IL-10 production while decreas-
ing IL-12 [56]. In addition, macrophages that have taken
up apoptotic cells are also able to suppress T-cell pro-
liferative responses whereas uptake of necrotic cells has
the opposite effect [57]. Defective uptake of apoptotic
cells, for example in mice deficient in the C1q complement
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Table 1. Pathogen associated molecular pattern recognition molecules on macrophage cell surface
Receptor Pathogen molecular pattern
TLR2 plus 1 or 6 (forming cell surface
receptor heterodimers) [41]
Zymosan, lipoproteins from Mycobacterium tuberculosis, Borrelia burgdorfei, Treponema
pallidum, and Mycoplasma fermentans, mycobacterial lipoarabinomannan, peptidoglycan,
Treponema glycolipid, Trypanosoma cruzi glycophosphatidylinositol anchor
TLR3 [39] Double-stranded RNA
TLR4 [41] Lipopolysaccharide (gram-negative bacteria), lipotechoic acid (gram-positive bacteria,
Mycobacterium tuberculosis, fusion proteins on respiratory syncytial virus (RSV), heat shock
protein 60 (HSP60) on Chlamydia pneumoniae
TLR5 [41] Flagellin
TLR9 [41] Unmethylated CpG DNA
Mannose receptor [196] Oligosaccharides, involved in recognition of bacteria (Klebsiella pnemoniae, Mycobacterium
tuberculosis) fungi (Crytococcus neoformans) viruses [human immunodeficiency virus (HIV)]
and protozoa (Pneumocystis carinii)
Scavenger receptor A [197] Lipotechoic acid, lipopolysaccharide, Staphylococcus aureus, Escherichia coli, Neisseria
meningitides, Clostridium perfringens
MARCO (macrophage receptor with a
collagenous structure) [198]
Escherichia coli, Staphylococcus aureus
Dectin-1 [199] b-glucans on zymosan, involved in fungal recognition.
component, leads to generation of autoantibodies and in
a proportion of mice the spontaneous development of
glomerulonephritis with increased local apoptotic bod-
ies [58]. Similarly, mice deficient in CD44 (hyalauronan
receptor) develop more severe bleomycin induced lung
inflammation due in part to impaired clearance of apop-
totic neutrophils [59].
As these studies show a large number of receptors can
potentially be involved in apoptotic cell uptake but the re-
cently identified phosphatidylserine receptor (PSR) plays
a significant role in development of the anti-inflammatory
phenotype [55]. Utilization of this mechanism has not
been directly applied to renal disease, however, in a
model of lung inflammation induced by LPS the intra-
tracheal instillation of apoptotic neutrophils markedly
reduced local chemokine production and total inflamma-
tory cell infiltrate and this was dependent on macrophage
uptake of the apoptotic cells and subsequent TGF-b pro-
duction [60]. It is likely that other apoptotic cell receptors
will play a similar role.
As yet no direct approaches to manipulate the up-
take of apoptotic cells have been tried in renal inflamma-
tion though some promising agents exist. These include
lipoxins which are endogenously produced anti-
inflammatory eicosanoids, for which synthetic analogues
also exist. Lipoxins increase macrophage uptake of apop-
totic neutrophils and decrease mesangial cell prolifera-
tion [61] and studies are currently assessing their ability
to influence renal inflammation [62, 63]. The augmented
uptake induced by lipoxins was not inhibited by blockade
of PSR showing the involvement of other macrophage re-
ceptors in apoptotic cell removal.
These examples have highlighted that as well as be-
ing involved in tissue damage macrophages can be inti-
mately involved in regulation and repair (Table 2). We
will now focus on the mechanisms that control these dif-
ferent states of activation.
Table 2. Macrophage activation states
Classically activated [45] ↑ iNOS, IL-1b , TNF-a, IL-6, HMGB1,
IL-8, MCP-1, MHC class II expression
Alternatively activated
(IL-4/IL-13) [45]
↑ Mannose receptor, MHC class II,
arginase, FIZZ1/Ym1, IL-1ra↓ iNOS,
TNF-a, IL-6
Type II activated [50] ↑ IL-10, TNF-a, IL-6, MHC class II↓
IL-12
Uptake of apoptotic cell
[54]
↑ TGF-b , PGE2,↓ TNF-a, IL-8, MCP-1
IL-10 activated [189] ↓ IL-1b , TNF-a, IL-12, IL-6, IL-8, iNOS,
MHC class II↑ Soluble TNF receptors,
IL-1ra
Steroid treated ↑ IL-10, uptake of apoptotic cells↓ IL-12,
TNF-a, IL-1b , IL-6
Abbreviations are: IL, interleukin; iNOS, inducible nitric oxide synthase;
TNF-a, tumor necrosis factor-a; HMGB1, high mobility group B1; MCP-1,
monocyte chemoattractant protein-1; MHC, major histocompatibility complex;
IL-1ra, IL-1 receptor antagonist; TGF-b , transforming growth factor-b ; PGE2,
prostaglandin E2.
CONTROL OF MACROPHAGE FUNCTION
VIA SURFACE RECEPTORS
As inflammation can have such deleterious conse-
quences for the host it is a tightly regulated system and
a number of receptors on macrophages have been iden-
tified which provide checks on the inflammatory cas-
cade. Thus, a key aspect of the inflammatory response
is the pairing of activation with inhibitory regulatory
signals and the loss of these signals often leads to
unchecked immune activation [64]. A number of recep-
tors have a negative regulatory effect on leukocyte func-
tion and often inhibit the function of immunoreceptor
tyrosine-based activation motif (ITAM) containing re-
ceptors. These counter-regulatory signals are provided
by the immunoreceptor tyrosine-based inhibitory mo-
tif (ITIM). The clustering of these motifs leads to
the binding and activation of SHP-1, which is a tyro-
sine phosphatase, and SHIP, which is an inositol phos-
phatase which transduce the negative regulatory signal.
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Table 3. Functions of suppressors of cytokine signalling (SOCS) in control of cell signaling [87]
Suppresors of cytokine signaling Induced Inhibits signaling
Cytokine-induced SRC-homology-2 IL-2, IL-3, IL6, IL-10 IL-2, IL-3, Epo, IGF-1
protein (CIS) [87]
SOCS1 [200] IL-2, IL-4, IL-6, IL-10, IFN-a/b/c, TNF IFN-c, IFN-b, IL-2, IL-4, IL-6, M-CSF
SOCS2 IL-2, IL-6, growth hormone Growth hormone
SOCS3 [88, 89] IL-6, IL-10, LPS, IL-11, IL-22, TNF IL-6, IFN-c, Epo
Abbreviations are: IL, interleukin; INF, interferon; TNF, tumor necrosis factor; Epo, erythropoietin; IGF-1, insulin-like growth factor-1; M-CSF, monocyte-colony
stimulating factor.
CIS and SOCS1 to 3 have been those best characterized and the cytokine or growth factor in bold represent those for which a physiologic role in control of signaling
is most likely. The role of SOCS4 to 7 in control of macrophage signaling is at this stage is unclear.
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Fig. 2. Regulation of macrophage function. Macrophage function is tightly regulated at a number of levels from the cell surface to the nucleus.
(1) Proinflammatory cytokines and pathogen associated molecular patterns activate cell surface receptors which leads to activation of a number
of intracellular signalling pathways including STAT1, nuclear factor-jB (NF-jB) and mitogen-activated protein kinases (MAPKs) which in turn
leads to the translocation of transcription factors to the nucleus (2) and activation a range of genes involved in the pro-inflammatory response
[82]. (3) Activation also increases production of molecules such as SOCS1 which inhibits activation by the interferon-c (IFN-c) receptor and IjB
and A20 which inhibit actions of NF-jB [83, 85]. (4) In addition, certain receptors such as FccRIIB contains an immunoreceptor tyrosine-based
inhibitory motif (ITIM) which activates SHP1 which is a phosphatase capable of negatively regulating a number of kinase related pathways. (5)
Other cells surface receptors activate signaling cascades which modulate and inhibit the inflammatory response and lead to a modified state of
activation which is principally anti-inflammatory in nature. (6) Uptake of apoptotic cells via the phosphatidylserine receptor (PSR) receptor leads
to transforming growth factor-b (TGF-b) production and reduced responsiveness to proinflammatory mediators. Abbreviations are: TNFR, TNF
receptor; TLR4, Toll-like receptor 4; IFNGR, IFN-c receptor; SHP1, Src homology 2 domain phosphatase; SOCS, suppressors of cytokine signalling;
MSP, macrophage stimulating protein.
A well characterized example of these competing influ-
ences is provided by the Fcc receptor. FccRIII is an
ITAM containing receptor which binds IgG immune
complexes and activates macrophages, including pro-
moting phagocytosis and release of pro-inflammatory
cytokines. FccRIIB by contrast is an ITIM receptor
which on binding IgG inhibits ITAM-triggered activa-
tion. The importance of this pathway is illustrated by
the observation that FccRIIB-deficient mice develop
more severe pulmonary inflammation in an immune
complex-induced disease with increased production of
pro-inflammatory cytokines by macrophages [65]. In ad-
dition these mice develop a Goodpasture’s syndrome on
immunization with type IV collagen and become sus-
ceptible to collagen-induced arthritis both marked by
macrophage activation [66, 67]. The therapeutic signif-
icance of this receptor was shown in a murine model
of immune thrombocytopenia where the protective
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effect of intravenous immunoglobulin was shown to be
dependent on the FccRIIB receptor, which in turn may
explain the value of intravenous immunoglobulin in treat-
ing immune-mediated inflammation [68].
Other counterregulatory receptors include CD200 re-
ceptor (CD200-R) which is a membrane glycoprotein
expressed by myeloid cells [69] and recognizes CD200
(OX-2) expressed on many cell types, including endothe-
lium. In a mouse model of experimental allergic en-
cephalomyelitis (EAE) inhibition of CD200-R using an
antibody worsened disease severity. In CD200-deficient
mice, EAE onset was accelerated, experimental uveo-
retinitis was more severe, and mice normally resistant
to collagen-induced arthritis developed disease [70, 71].
Thus CD200-macrophage interaction could be viewed as
providing an early restraint on macrophage responses at
the tissue level.
Another recently identified regulator of macrophage
function is the CD47-signal regulatory protein-alpha
(SIRPa) (CD172a) interaction [72]. CD47 is ubiquitously
expressed, while SIRPa is limited to myeloid cells. En-
gagement of SIRPa activates ITIM which leads to re-
cruitment and activation of SHP-1 and SHP-2, which in
turn inhibit tyrosine kinase-dependent activation path-
ways [73]. Activation of SIRPa inhibits maturation of
dendritic cells with reduction of costimulatory molecule
expression and suppresses production of TNF-a, IL-12,
and IL-6 in response to LPS [74, 75], while expression of
CD47 on red blood cells prevents their phagocytosis by
macrophages by activating SIRPa [76].
Macrophage-stimulating protein (MSP) is produced
as a promolecule in the liver which is then activated
by factors from the coagulation cascade at sites of lo-
cal inflammation. MSP binds to stem cell–derived ty-
rosine kinase receptor (STK/RON) which is expressed
on macrophages (reviewed in [77]). MSP-RON interac-
tion inhibits LPS and IFN-c–induced nitric oxide produc-
tion [78], increases arginase expression, and up-regulates
other genes associated with alternative macrophage ac-
tivation, including scavenger receptor A and IL-1ra [79].
In addition, mice which lack STK/RON have increased
inflammation in IFN-c–mediated delayed-type hypersen-
sitivity response, increased susceptibility to LPS-induced
shock, and macrophages isolated from these mice pro-
duce elevated levels of nitric oxide in response to IFN-
c [80]. There is also evidence that LPS can reduce
RON expression in vitro and in vivo [81]. Thus this sys-
tem may provide an important check on the control of
macrophage-mediated inflammation although its role in
models of immune disease has not been assessed.
These examples show clear evidence of negative regu-
latory pathways controlling macrophage function which
provide additional checkpoints in the inflammatory re-
sponse. Other examples include more classical cytokine
receptor responses such IL-4, IL-10, and IL-13 which
can combine with the above signals to significantly alter
macrophage function.
SIGNALING PATHWAYS CONTROLLING
MACROPHAGE FUNCTION
The previous sections illustrates that macrophage func-
tion is regulated by the signals impinging on surface
receptors and the interplay between opposing surface
receptors. Ultimately, events on the cell surface lead to
activation of signaling cascades and specifically to acti-
vation of transcription factors. Two of the key groups of
transcription factors are NF-jB activated by inflamma-
tory mediators such TNF-a, IL-1b , and LPS and STAT
family which transduce signals from IFNs, IL-12, IL-6,
IL-4, IL-13, and IL-10 [82]. As with cell surface receptors
these signals are carefully regulated within the cell to pre-
vent excessive activation. NF-jB is family of 5 proteins
(p65, Rel-A, c-Rel, p50, and p52) which are bound by an
inhibitory protein IjB in the cytosol [83]. Activation of
signalling cascades leads to the phosphorylation of IjB
by IjB kinases, which results in the ubiquitination of IjB,
degradation by the 26S proteosome and release of NF-jB
molecules. These in turn form heterodimers and homod-
imers which enter the nucleus and activate transcription
of NF-jB–dependent genes which include TNF-a, IL-1b ,
IL-8, leukocyte function-associated molecule-1 (LFA-1),
very late antigen-4 (VLA-4), costimulatory molecules
CD80 and CD86, and IL-10. NF-jB also increases expres-
sion of IjB which then binds and removes NF-jB from
the nucleus [84]. Similarly A20 is a cytoplasmic protein
which can also inhibit NF-jB activation [85] and its ex-
pression is increased by TNF-a, and may have particular
relevance in terminating TNF-induced inflammation [86].
The JAK-STAT family of proteins are responsible for
signaling from a wide range of cytokines in macrophages
including IFN-c (STAT1), IL-6 (STAT1 and 3), IL-10
(STAT3), and IL-12 (STAT4) [82]. IFN-c and IL-12 both
promote the inflammatory response while IL-10 provides
critical regulation of inflammation and as later sections
will show is of potential therapeutic value. Negative regu-
lation of these signaling pathways is provided by members
of the suppressor of cytokine signaling (SOCS) family of
which eight have been identified so far (Table 2) [87]. The
best characterized include SOCS-1 which is up-regulated
by IFN-c and in turn binds to and inhibits kinase activ-
ity of JAK2 to inhibit IFN-c signaling, while SOCS3 has
recently been identified as the key inhibitor of the IL-6-
STAT3 pathway [88, 89]. Again these pathways prevent
unrestrained inflammatory activity which is seen in the
SOCS1−/− mouse [90].
Other transcription factors involved in the regu-
lation of macrophage activation include peroxisome
proliferators-activated receptor-c (PPAR-c) [91]. This
family of transcription factors was originally identified
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for their role in glucose and lipid metabolism; however,
they are also involved in control of inflammation. PPAR-
c expression is increased in macrophages by IL-4 [92]
and PPAR-c ligands, including the thiazolidinedione class
of type II diabetic drugs, result in reduced IL-6, TNF-a,
IL-1b and IL-12 expression [93] and decreased iNOS ex-
pression [94]. Thus cytokines cell surface proteins and
intracellular signaling pathways form a multilayered net-
work in macrophages and other cells involved in the im-
mune response to contain and curtail inflammation.
MODIFICATIONS OF MACROPHAGE
FUNCTION BY DISEASE STATES
The importance of the state of macrophages activa-
tion in controlling inflammation is most clearly high-
lighted in diseases which bias macrophage activity to
prevent development of the immune response, in par-
ticular certain infectious diseases and malignancy [95–
97]. Numerous pathogens have developed strategies to
subvert macrophage function to dampen the innate in-
flammatory response and these provide an insight into
how macrophages might be manipulated therapeutically.
Yersinia enterocolitica inhibits the activation of NF-jB
in macrophages leading to reduced TNF-a secretion and
cells becoming apoptotic with consequent immunosup-
pressive effects on uptake [98], while Yersinia pestis pro-
duces a virulence protein, LcrV, which interacts with
TLR2 and increases IL-10 production which in turn re-
duces the inflammatory response [99]. The African swine
fever virus which replicates in macrophages produces an
IjB-like protein which reduces NF-jB activation [100].
Leishmania spp bind to the PSR receptor thus appear
to the macrophage as an apoptotic cell with consequent
anti-inflammatory release of TGF-b and IL-10 [101, 102].
Similarly uptake of apoptotic T cells by macrophages in-
fected with Trypanosoma cruzi dampens their inflam-
matory response and promotes parasite growth [103].
Toxoplasma gondii is another intracellular parasite which
on macrophage interaction causes NF-jB and STAT1 ac-
tivation but prevents their nuclear entry to switch off the
antimicrobial response [104].
Tumor-associated macrophages (TAM) are found in
nearly all tumors and although they have the potential to
kill malignant cells their function is frequently subverted
to promote tumor development [96]. Tumors can produce
a number of anti-inflammatory cytokines, including IL-4,
IL-10, TGF-b , and PGE2 which suppress cell-mediated
immune responses. TAM have a reduced ability to pro-
duce IL-12 which is a result of autocrine IL-10 production
[105] and similarly dendritic cells from tumors have an im-
mature phenotype and are refractory to stimulation with
LPS and IFN-c due to IL-10 production [106]. In addition,
macrophage infiltration actually favors tumor growth and
metastasis by production of proteases which degrade ex-
tracellular matrix allowing tumor infiltration and angio-
genic factors such as vascular endothelial growth factor
(VEGF) which promote vascular growth [107]. Thus, the
complex relationship between tumor and macrophage
shows how deviating macrophage function can prevent an
inflammatory response. These examples provide a clear
rationale to alter macrophage activation to control local
inflammation.
MACROPHAGE LOCALIZATION
IN RENAL INFLAMMATION
Macrophage adhesion
The first stage of macrophage involvement in inflam-
matory renal disease involves their adhesion to and
migration across endothelium. The classic paradigm of
leukocyte adherence to inflamed endothelium involves
lectin interaction which allows leukocyte rolling, this
in turn leads to adherence of integrins such as LFA-1
and mac-1 to intercellular adhesion molecule (ICAM-1)
and VLA-4 to vascular cell adhesion molecule (VCAM),
which firmly binds the leukocyte to the endothelium and
allows diapedesis to occur [108]. It is though increasingly
clear that different vascular beds within the body and
different forms of inflammation may utilize distinct ad-
herence pathways [109]. The role of selectins in glomeru-
lar inflammation is still controversial but administration
of fucoidan F7 which inhibits L- and P-selectin func-
tion failed to alter glomerular leukocyte localisation in
nephrotoxic nephritis [110]. In the same disease model
P-selectin–deficient mice developed more severe disease
most likely due to loss of anti-inflammatory effect of
soluble P-selectin [111]. In WKY rats with crescentic
glomerulonephritis, by contrast, anti-P-selectin antibody
reduced macrophage infiltration and crescent formation
[112]; however, this may represent a nuance of the WKY
rat model.
Blockade of ICAM-1 or its counter-receptor LFA-
1 with antibodies reduced macrophage infiltration in
WKY rats with nephrotoxic nephritis [113, 114]; however,
these rats have an abnormal immune response and de-
velop very severe glomerular inflammation unlike other
rat strains, thus the responses may not be representa-
tive. Interestingly administration of anti-CD18 antibod-
ies (counterreceptor to ICAM-1 and 2) in Lewis rats with
nephrotoxic nephritis did not reduce macrophage infil-
tration [115] and similarly blockade of either VCAM or
its ligand VLA-4 did not reduce macrophage recruitment
in the same disease model [116]. In both of these latter
studies macrophage infiltration was not altered however
disease was less severe, again demonstrating the
disassociation of macrophage numbers from injury.
Recently interest has focused on chemoadhesins, in-
cluding fractalkine and GRO-a (CXCL1). Fractalkine is
a chemokine which contains a transmembrane domain
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allowing it to be expressed as an endothelial cell surface
protein [117], and inhibition of its receptor, CX3CR1,
markedly reduced macrophage infiltration in a model
of crescentic glomerulonephritis [118]. GRO-a can be
immobilized on cell surface proteoglycans which are
up-regulated on inflamed endothelium and mediate ad-
herence under conditions of flow [119]. In rats with
nephrotoxic nephritis direct blockade of GRO-a recep-
tor on macrophage surface reduced their localization to
inflamed glomeruli [120].
ROLE OF CHEMOKINES IN
MACROPHAGE LOCALIZATION
Following adhesion to activated endothelium macro-
phages transmigrate to the focus of injury in response
to a chemotactic gradient. A wide range of studies have
confirmed their importance in macrophage infiltration
in a variety of renal diseases (reviewed in [121]). The
main challenge now is to establish which chemokines
are critical for pathogenesis, which could potentially fa-
vor entry of reparative macrophages and how adhesion
and transmigration alter macrophage function. Renal in-
jury, whether toxic, ischemic, or immunologic, can lead to
chemokine production by endothelium, mesangial cells,
or tubular cells. Many studies have been performed on hu-
man biopsies to demonstrate expression of chemokines
and their relevant receptors. The most extensively as-
sessed have been MCP-1 and its receptor CCR2, and
RANTES, macrophage inflammatory protein-1a and 1b
(MIP-1a and MIP-1b) and their receptors CCR1, 3, and
5 due to their well characterized effect on macrophage
chemotaxis [122]. MCP-1 and CCR2 have been found
in IgA disease [123], crescentic glomerulonephritis, in-
cluding ANCA-positive disease and lupus nephritis [124–
126], and in acute interstitial nephritis [123]. In IgA dis-
ease MCP-1 expression was associated with more severe
disease and a number of studies have correlated urinary
MCP-1 levels with severity of renal injury [127–130]. Sim-
ilarly MIP-1a, MIP-1b , and RANTES or their recep-
tors have been identified in lupus nephritis, crescentic
glomerulonephritis, and IgA disease [126, 129, 131].
The presence of the relevant chemokines as a snap shot
in human biopsies tells us relatively little about their func-
tions, in particular how chemokine and chemokine re-
ceptor expression varies with stage of disease, in specific
inflammatory cells and in different locations within the
kidney. For this we have to turn to animal models. In-
teresting data have been provided by knockout mice for
chemokines and their receptors. In mouse nephrotoxic
nephritis, MCP-1 was mainly expressed in tubular cells
and MCP-1–deficient mice developed less severe tubu-
lar injury while glomerular macrophage infiltration and
subsequent inflammation were unaltered suggesting that
MCP-1 primarily directs macrophages to the interstitium
[132]. In the MRL-Fas (lpr) lupus model, MCP-1 defi-
ciency reduced tubular and glomerular macrophage in-
filtration and protected from severity of disease [133]. In
contrast to these results, knockout of the MCP-1 receptor
CCR2 led to more severe disease in mice with nephro-
toxic nephritis, despite resulting in reduced glomerular
macrophage infiltration [134]. Similar to this in the same
model knockout of CCR1 (receptor for RANTES and
MIP-1a) led to increased renal macrophage infiltration,
more severe disease and biased disease toward a Th1 phe-
notype [135]. These experiments highlight the complex-
ity of chemokine control of leukocyte function as there
effects are not limited to the kidney but alter both the bi-
ology of cells and their trafficking in other sites within the
body that may have important pathologic consequences.
A number of recent studies have focused on the
temporal organization of chemokine expression in re-
nal inflammatory models and how these might coor-
dinate macrophage entry. Reversible immune complex
glomerulonephritis in mice can be induced by injection of
horse apoferritin and in this model MCP-1 and RANTES
and their relevant counterreceptors are expressed early
on in disease and precede both the peak of biochemi-
cal and histologic injury [136] as inflammation resolves
chemokines and receptor expression returns to base-
line levels. Similar results were observed in a progres-
sive model of inflammation in lupus mice with early
expression of MCP-1 and RANTES in glomeruli and
interstitium which preceded the influx of mononuclear
cells and proinflammatory cytokine expression [137]. In
rat nephrotoxic nephritis MCP-1 and RANTES are ex-
pressed in glomeruli as inflammation is initiated, but
with only limited tubular MCP-1 expression. By con-
trast tubular levels of osteopontin, a potent macrophage
chemokine were elevated [138]. These studies show a
coordinated chemokine response both over time and in
different locations within the kidney which orchestrate
macrophage infiltration.
Despite the reservations about the precise role of
chemokines in regulating macrophage infiltration, a num-
ber of studies have assessed the impact of inhibiting
specific chemokines receptors. Anti-MCP-1 antibody re-
duced macrophage infiltration, crescent formation, and
proteinuria in WKY rats and mice with nephrotoxic
nephritis [139–141] and in rats with anti-Thy 1.1 nephri-
tis [142]. In mice with nephrotoxic nephritis blockade of
MCP-1 or RANTES resulted in a reduction in glomeru-
lar macrophage infiltration but only anti-MCP-1 an-
tibodies reduced crescent formation and collagen de-
position [143]. Contrasting with these results in WKY
rat nephrotoxic nephritis anti-MCP-1 treatment reduced
macrophage infiltration early on but not after first week
of disease which suggests that MCP-1 may be the initial
chemotactic stimuli but that progression of disease may
depend on other stimuli [144]. Herpes virus 8 produces
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a chemokine analogue vMIP-II which is able to block
macrophage chemotactic responses to MCP-1, MIP-1a
and b , RANTES and fractalkine. In WKY rats with cres-
centic glomerulonephritis vMIP-II reduced macrophage
infiltration, crescent formation, and proteinuria while
preserving renal function [145]. RANTES function can be
blocked by two synthetic antagonists amino-oxypentane
RANTES (AOP-RANTES) and Met-RANTES. AOP-
RANTES blocked the early influx of macrophages
during anti-Thy 1.1 nephritis in rats and murine nephro-
toxic nephritis [141, 146]. In immune complex glomeru-
lonephritis, however, treatment with AOP-RANTES or
Met-RANTES both reduced glomerular macrophage in-
filtration but actually resulted in more severe inflam-
mation [147], which emphasizes that it is macrophage
function not numbers that will be crucial in control-
ling disease. More recently, an important role has been
proposed for macrophage-derived chemokine (MDC),
where blockade of its function in WKY rat nephrotoxic
nephritis did not alter initial development of glomerular
inflammation but reduced macrophage infiltration and
crescent formation from days 7 to 14 of disease [148].
Clearly inhibiting macrophage infiltration represents
one approach to modify renal inflammatory disease. An
overview of all the studies presented here shows that
there are clear species and disease model differences in
the relative importance of different chemokines but what
is still needed is a better understanding of how chemokine
selection dictates the function of infiltrating macrophages
and how this changes as disease evolves.
MACROPHAGE ACTIVATION DURING
RENAL INFLAMMATION
How macrophages interact with inflamed glomeruli
at a single cell level has been less extensively assessed.
In part this is due to a relative paucity of markers
which clearly delineate different states of activation,
although this is being addressed by gene chip analy-
sis of macrophage expression under specific conditions
[149]. Work from our group has shown that certain ac-
tivating signals, such as IFN-c and TNF-a, programmed
macrophages to developed distinct sets of properties in
vitro, which included unresponsiveness to other types
of activation [150]. Furthermore, macrophages infiltrat-
ing acutely inflamed glomeruli of rats with nephrotoxic
nephritis display programmed behavior. Operationally,
they behave as though programmed by IFN-c [44], and
maintain these characteristics despite systemic adminis-
tration of alternatively activating cytokines such as IL-4
or TGF-b . Interestingly, the IFN-c–driven program pre-
dominates when immune mediated injury occurs in a
TGF-b–rich environment such as the eye [151]. Subse-
quent observation in anti-Thy 1.1 nephritis has shown that
(1) macrophage localization itself does not induce pro-
gramming; (2) that all macrophages infiltrating an appro-
priate environment become programmed shortly after
localization; and (3) macrophages infiltrating glomeruli at
the same time can be programmed in different ways [152].
These observations raise question about the factors that
induce macrophage activation and programming at early
stages of the inflammatory disease and its consequences
for the outcome of the inflammatory process. It provides
an important mechanistic insight into how macrophage
functional development is influenced by the underlying
disease process.
Comparison of macrophage infiltration in ANCA-
positive vasculitis and cryoglobulinemic vasculitis shows
that a similar heterogeneity exists in human glomeruli.
In ANCA-positive disease macrophages were localized
at sites of active lesions and were MHC class II and TNF-
a–positive while in cryoglobulinemia they were diffusely
localized in glomeruli and less than 30% of macrophages
had these same markers of activation [153].
Thus macrophages both respond to and produce proin-
flammatory cytokines within foci of renal inflammation
and a recent series of studies has attempted to dissect
their relative contributions. Using bone marrow chimeras
in knockout mice Timoshanko et al [154, 155] have shown
that TNF-a and IL-12 production during nephrotoxic
nephritis in mice is mainly dependent on intrinsic re-
nal cells rather than infiltrating leucocytes, while IFN-c
production requires contributions from both [156], with
macrophage production potentially as significant as the
T-cell contribution [157].
MACROPHAGE FATE DURING
PROGRESSIVE INFLAMMATION
After the initial influx of macrophages, there is increas-
ing evidence that the subsequent sustained increase in
macrophage numbers is a result both of continuing in-
flux and local proliferation [158]. Expression of prolifer-
ating cell nuclear antigen (PCNA) and incorporation of
bromodeoxyuridine (BrdU), which are markers of pro-
liferation, can be found in around half of glomerular and
tubulointerstitial macrophages in rat nephrotoxic nephri-
tis and rat remnant kidney model [159, 160]. Proliferation
was seen mostly in ED-1–positive macrophages and not
in ED-2 or ED-3–positive cells which tend to be markers
of more mature or activated tissue macrophages. Prolif-
erating macrophages have also been identified in human
renal biopsies [161]. Possible growth factors which con-
trol this include macrophage-colony stimulating factor
(M-CSF) which is involved in macrophage differentia-
tion. Blockade of its receptor, c-fms, reduces macrophage
accumulation in unilateral ureteric obstruction in mice by
markedly reducing macrophage proliferation [162].
The fact that there is continuous macrophage entry
into a focus of renal inflammation and proliferation of
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macrophages emphasises the need to understand the
fate of these cells. The two possibilities are death within
the glomerulus or interstitium or emigration to regional
lymph nodes. As yet there is no evidence of widespread
macrophage apoptosis in inflamed kidneys but the rapid
removal of apoptotic cells is beyond the resolution of cur-
rent techniques. However, cell death could still provide
an important contribution. Macrophage migration to re-
gional lymph nodes has been demonstrated in rats with
nephrotoxic nephritis [163]. In a mouse model of resolv-
ing peritonitis fluorescently labeled macrophage could
be tracked to draining lymph nodes and emigrated with
a half-life of 48 hours [164]. This process has recently
been shown to be actively mediated and partially depen-
dent on VLA-4 and VLA-5 [165]. In our own studies
where we have injected labeled adenoviral-transduced
macrophages into rats with nephrotoxic nephritis these
cells disappear from inflamed glomeruli again with a half-
life of approximately 48 hours [166, 167]. These data im-
ply that macrophages are continually trafficking through
a site of inflammation and provide a feedback of infor-
mation to the immune response.
Thus the potential maturation of these cells to dendritic
cells which can then inform T-cell responses is a critical
issue. A model system for this is provided in vitro where
macrophages transmigrate across endothelium placed on
a collagen gel [168]. Macrophages reverse migrate across
the endothelium with a half-life of 48 hours while some
macrophages remained within the gel. When the collagen
gel was exposed to proinflammatory stimuli such as LPS
or IL-1b the reverse migrated macrophages resembled
mature dendritic cells expressing MHC class II, costim-
ulatory molecules and the dendritic cell marker CD83,
as well as losing expression of CD14 and Fc receptors.
Those that remained behind in the gel resembled tis-
sue macrophages [169]. More recent data suggests that
a subset of monocytes expressing FccrIII (CD16) prefer-
entially become dendritic cells in this setting [170]. It has
also been shown that TNF-a and IL-1 promote migration
of Langerhans-type dendritic cells from skin [171]. Thus
it is likely that macrophages/dendritic cells migrate to re-
gional lymph and are a critical link in the inflammatory
response.
IMMUNE MODULATION OF RENAL
INFLAMMATORY DISEASE
Given the diverse functions of macrophages in renal in-
flammatory disease and there ability to respond to a wide
range of inputs manipulation of their function provides
an attractive approach to alter inflammation.
Cytokines
We have already shown how blockade of proinflamma-
tory cytokines such as TNF-a and IL-1b and chemokines
can decrease the inflammatory response. The alterna-
tive is to use the cytokine network to promote an anti-
inflammatory response [27]. IL-4 is produced by Th2 cells
and leads to alternative activation of macrophages. In-
jection of IL-4 into rats with nephrotoxic nephritis re-
duced the degree of proteinuria, increased glomerular
expression of IL-1ra, and limited macrophage activa-
tion as shown by reduced glomerular ED-3+ cells [172].
In Heymann’s nephritis treatment with IL-4 prevented
the development of proteinuria and reduced glomeru-
lar macrophage infiltration, although this effect appeared
dependent on IL-4 effects on T cells [173]. IL-10 is a crit-
ical regulatory cytokine and its administration to mice
with nephrotoxic nephritis ameliorates disease severity
and reduces macrophage activation as shown by reduced
MHC class II and IL-1b expression and nitric oxide
generation [174]. In Thy 1.1 nephritis IL-10 treatment
reduced glomerular macrophage infiltration and IL-1b
expression, as well as reducing mesangial cell prolif-
eration [175]. By contrast in lupus prone NZB/W F1
mice anti-IL-10 antibodies reduced glomerular inflam-
mation and improved survival, an effect due in part to
up-regulation of TNF-a [176]. Which cells are critical for
this TNF-a production is unclear. IL-11 inhibits LPS in-
duced TNF-a, IL-1b , and IL-12 in macrophages [177] and
administration to WKY rats with nephrotoxic nephritis
reduced macrophage infiltration, proliferation and level
of proteinuria [178].
One of the functions of macrophages/dendritic cells
is to present antigen to T cells. This requires a cognate
interaction between MHC class II and the T-cell recep-
tor along with CD80 and CD86 binding to T-cell CD28
providing costimulation. This process can be blocked by
soluble CTLA-4 and administration of this to WKY rats
with nephrotoxic nephritis reduced antiglomerular base-
ment membrane antibody production, macrophage and
T cell glomerular infiltration, and proteinuria [179].
Inhibition of signaling pathways
Most of the approaches outlined above alter macro-
phage function by activating or inhibiting intracellular
signaling pathways and a number of strategies exist to
directly affect these. NF-jB is a central regulator of
proinflammatory gene expression and inhibition of it by
steroids at least in part explains their anti-inflammatory
effect in experimental renal inflammation [180]. A more
specific approach involves blocking NF-jB by transduc-
ing glomerular cells with NF-jB decoy deoxyoligonu-
cleotides (ODN) administered by direct renal artery
injection [181]. In rats with nephrotoxic nephritis decoy
NF-jB ODN reduced leukocyte infiltration, proteinuria,
and proinflammatory cytokine expression. Administra-
tion of parthenolide, a plant extract which inhibits NF-
jB activation, in Thy 1.1 nephritis, reduced proteinuria
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and macrophage infiltration and similarly in antimesan-
gial cell nephritis in mice gliotoxin, a fungal metabolite
with similar NF-jB inhibitory activity, reduced protein-
uria and hematuria [182]. The MAPK pathway also
plays a role in proinflammatory activation of cells and
pharmacologic inhibition of p38-MAPK reduced the
early development of glomerular inflammation in rat
nephrotoxic nephritis [183]. With all of these studies the
inhibitors operate on all the cells within the kidney (en-
dothelium, tubular cells, podocytes, and inflammatory
cells) as well as cells involved in generation of the immune
response out with the kidney, so determining which are
the critical sites of regulation will require a more specific
approach.
Genetic manipulation of macrophage function
This review has focused on the concept that the patho-
genetic or reparative roles of macrophages in inflam-
matory renal disease are determined by their state of
activation and that strategies aimed at altering macro-
phage activation should have therapeutic benefit. One
test of this hypothesis is to directly alter macrophage
function ex vivo and determine their effects when these
cells are delivered to inflamed kidneys. Genetic modifi-
cation of macrophages provides such a direct approach
to harness the ability of macrophages to regulate inflam-
mation. A number of groups have shown the potential
for this in both glomerular and interstitial disease [166,
184, 185]. The most effective method for transduction
of macrophages routinely available is recombinant ade-
novirus which provides good short-term expression in a
large proportion of cells, although lentiviruses are more
effective for long-term stable expression [186]. The ma-
jority of approaches so far have focused on macrophages
expressing anti-inflammatory or regulatory cytokines.
Systemic injection of macrophages transduced with re-
combinant adenovirus to express IL-1ra reduced the
severity of glomerular inflammation in mice with nephro-
toxic nephritis and reduced interstitial macrophage in-
filtration in a model of unilateral ureteric obstruction
[187, 188], with transduced cells producing the cytokine
for up to 4 weeks in vivo. We have shown that NR8383
cells expressing rat IL-4 localized efficiently to inflamed
glomeruli of rats with nephrotoxic nephritis following di-
rect injection into the left renal artery, produced the cy-
tokine locally and reduced macrophage infiltration, his-
tologic markers of glomerular inflammation, and protein-
uria for up to 7 days [167]. In the same model injection of
primary cultures of rat BMDM transduced to express IL-
10 similarly produced a marked reduction in albuminuria
and macrophage activation as demonstrated by reduced
MHC class II and ED-3 expression [189]. The impact of
IL-10 expressing cells was more pronounced than IL-4
with the most significant differences in injury seen 7 days
after a single injection of cells. In these experiments there
is no evidence of systemic production of cytokine; how-
ever, the localized glomerular production will not only
alter the function of transduced macrophages but also af-
fect other infiltrating macrophages, endothelial cells, and
resident glomerular cells, including mesangial cells and
podocytes.
These latter experiments produced the interesting ob-
servation that following injection of macrophages into
a single kidney the changes in macrophage activation
and histologic markers of inflammation were reduced in
the injected kidney and in the contralateral glomeruli.
This contralateral effect occurred in the absence of sys-
temic IL-4 or IL-10 expression, with very few transduced
cells localizing to the contralateral kidney and could not
be mimicked by systemic injection of cells. A similar
phenomenon was found in experimental arthritis where
transduction of one joint with IL-1ra or TNF-a antag-
onist reduced inflammation at distant joints [190]. The
favored mechanism behind this effect is that the expres-
sion of regulatory cytokines within an inflamed site al-
ters the function of dendritic cells which migrate to re-
gional lymph nodes and modifies the systemic immune
response. Certainly in mouse arthritis models transduc-
ing dendritic cells to express IL-4 suppresses inflamma-
tion on systemic administration [191, 192]. These experi-
ments demonstrate that the infiltration of a small number
of macrophages, with altered function, is able to produce
sustained reorientation of the inflammatory response.
The main problem with the use of replication defective
adenovirus to transduce macrophages is that expression
is not regulated and is short term. To achieve inflamma-
tory specific expression macrophages can be transduced
with two recombinant adenoviruses [193]. The first con-
tains the IL-1b promoter which controls expression of
Cre recombinase that in turn excises DNA from a second
adenovirus carrying a reporter gene under the control of
strong viral promoter, leading to reporter gene expres-
sion. Using this approach relevant transgene expression
was found in inflamed glomeruli of mice with nephrotoxic
nephritis but not in noninflamed sites [193]. To achieve
longer term expression in macrophages requires integra-
tion of the relevant cDNA into the genome. This can
be achieved by retroviral transformation of bone mar-
row stem cells which then differentiate into macrophages.
Bone marrow cells derived in this fashion have been
transduced to express IL-1ra. Long-term expression of
IL-1ra was found in vivo and development of nephro-
toxic nephritis was retarded in mice receiving these cells
[194]. For humans such CD34+ stem cells can potentially
be obtained from human cord blood. In a recent study
human CD34+ cells were retrovirally transduced to ex-
press b-glucuronidase as a marker gene and injected into
NOD/SCID mice. When these mice were treated with
LPS CD14+ cells were recruited to the glomeruli and
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secreted the transgene, thus showing that modified hu-
man stem cells can mature to macrophages in vivo [195].
CONCLUSION
A wide range of experimental intervention studies
have shown that altering the local or systemic inflamma-
tory environment will alter macrophage function. Per-
haps more tellingly they have also made other critical
observations: (1) reduction in injury is associated with
changes in markers of macrophage function, (2) there is
a dissociation between macrophage numbers in inflamed
sites and severity of injury when disease is modified, and
(3) macrophage function can be altered by genetic manip-
ulation to regulate inflammation. Thus macrophage func-
tion appears more important then the absolute number
of infiltrating cells in the control renal inflammation. As
understanding of the heterogeneity of macrophage func-
tion in inflammation has increased so has the potential
to utilize macrophages to regulate and switch off injury.
The future will allow further assessment of macrophage
inhibitory receptors and anti-inflammatory mediators to
alter renal inflammatory disease. There is also increasing
appreciation that “nonimmune” diseases such as diabetic
nephropathy and progressive renal failure have a signifi-
cant inflammatory component which may be amenable to
therapy. Finally, the potential for both novel therapeutic
agents and genetic modification to bias rather than switch
off macrophage function will offer new approaches to
treat renal disease.
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